Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

First International Summit on Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Jul

Today In Oncology

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Metastatic Castration-Resistant Prostate Cancer Comparison of Second-Line Regimens

AI-Enhanced PACT as a Noninvasive Breast Imaging Alternative

HER3-DXd in NSCLC Without EGFR-Activating Mutations

Survey Shows Inaccuracies in US Perceptions of Testicular Cancer

utDNA May Help to Personalize Bladder Cancer Treatment